Avinger Inc. (AVGR) Sees Strong Trading Volume
Shares of Avinger Inc. (NASDAQ:AVGR) saw unusually-strong trading volume on Friday . Approximately 559,820 shares were traded during mid-day trading, an increase of 47% from the previous session’s volume of 382,025 shares.The stock last traded at $3.67 and had previously closed at $3.75.
A number of research analysts recently weighed in on AVGR shares. Zacks Investment Research downgraded shares of Avinger from a “hold” rating to a “sell” rating in a research report on Monday, May 9th. Canaccord Genuity reaffirmed a “buy” rating on shares of Avinger in a research report on Tuesday, July 12th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $18.00 target price on shares of Avinger in a research report on Friday, July 15th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $18.75.
The stock’s market capitalization is $47.00 million. The company’s 50-day moving average price is $7.69 and its 200 day moving average price is $11.07.
Avinger (NASDAQ:AVGR) last issued its quarterly earnings results on Monday, August 1st. The medical device company reported ($1.06) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.15) by $0.09. The firm earned $4.70 million during the quarter, compared to analyst estimates of $3.05 million. On average, analysts expect that Avinger Inc. will post ($4.36) earnings per share for the current year.
Avinger, Inc is a commercial-stage medical device company. The Company designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral arterial disease (PAD). The Company focuses on introducing products based on its lumivascular platform, which is an intravascular image-guided system.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.